The initial success of Sildenafil undeniably reshaped the pharmaceutical landscape, but betting in companies heavily reliant on generic versions presents a uncertain picture. While early returns were impressive, the cessation of patents and the emergence of less expensive alternatives have eroded the customer base. Consequently, a thorough assessme